Holen Sie sich die Stockscreener-App
32.96
3.57%
-1.22
Vorhandelsmarkt:
33.10
0.14
+0.42%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Privium Fund Management B.V. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 2,243 shares in open-market trade - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Quantisnow
Hussman Strategic Advisors Inc. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Baruch S. Ticho sells STOK shares under 10b5-1 (STOK) - Stock Titan
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome (STOK) - Seeking Alpha
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates - BioSpace
Epilepsy Pipeline Grows as 75+ Pharma Companies Advance 90+ - openPR.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(STOK) Volatility Zones as Tactical Triggers - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
STOK Should I Buy - Intellectia AI
[ARS] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Executive pay, board elections and new auditor at Stoke Therapeutics (NASDAQ: STOK) - Stock Titan
De-Risked Phase 3 Design and Durable Efficacy Support Buy Rating on Stoke Therapeutics’ Zorevunersen - TipRanks
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo
STOK: Zorevunersen shows sustained efficacy and cognitive gains, with phase III readout expected mid-2027 - TradingView
Price-Driven Insight from (STOK) for Rule-Based Strategy - Stock Traders Daily
Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Fed Meeting: Is Stoke Therapeutics Inc a strong candidate for buy and hold2026 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Treasury Yields: Is Stoke Therapeutics Inc a cyclical or defensive stock2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - NTB Kommunikasjon
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Stoke Therapeutics Appoints Clare Kahn, Ph.D. to Board and Advances Zorevunersen for Dravet Syndrome Treatment - Minichart
Stoke Therapeutics Appoints Clare Kahn to Board - citybiz
Stoke Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Stoke Therapeutics (STOK) director receives 30,782-share stock option grant - Stock Titan
Stoke Therapeutics (STOK) director Kahn Clare submits initial Form 3 insider report - Stock Titan
Stoke Therapeutics appoints Clare Kahn to board of directors By Investing.com - Investing.com India
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight - TipRanks
Stoke Therapeutics appoints Clare Kahn to board of directors - Investing.com
Clare Kahn joins Stoke Therapeutics (Nasdaq: STOK) board, receives option grant - Stock Titan
Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026 - marketscreener.com
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors - Yahoo Finance
Trading Recap: Can Stoke Therapeutics Inc grow without external fundingQuarterly Market Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus - Yahoo Finance
Should I Buy Stoke Therapeutics (STOK) Stock in 2026 | Price at $32.93, Up 0.57%Social Trading - Xã Vĩnh Công
Growth Value: What is the earnings history of Stoke Therapeutics Inc2026 Major Catalysts & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Stoke Therapeutics (STOK) CMO sells 1,838 shares in planned open-market trade - Stock Titan
(STOK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - MSN
Insider sells shares under 10b5-1 — STOK (NASDAQ: STOK) discloses trades - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stoke Therapeutics (STOK) price target increased by 12.11% to 43.96 - MSN
Stoke Therapeutics Hits Day High with 7.98% Surge in Strong Intraday Performance - Markets Mojo
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares - AOL.com
Stoke Therapeutics, Inc. Files 8-K Announcing Change in Certifying Accountant – March 2026 - minichart.com.sg
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):